179 related articles for article (PubMed ID: 11398170)
1. Comparison of prazosin, terazosin and tamsulosin: functional and binding studies in isolated prostatic and vascular human tissues.
Amadesi S; Varani K; Spisani L; Daniele C; Turini A; Agnello G; Zamboni P; Borea PA; Geppetti P
Prostate; 2001 Jun; 47(4):231-8. PubMed ID: 11398170
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.
Kenny BA; Miller AM; Williamson IJ; O'Connell J; Chalmers DH; Naylor AM
Br J Pharmacol; 1996 Jun; 118(4):871-8. PubMed ID: 8799556
[TBL] [Abstract][Full Text] [Related]
3. Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery.
Testa R; Guarneri L; Taddei C; Poggesi E; Angelico P; Sartani A; Leonardi A; Gofrit ON; Meretyk S; Caine M
J Pharmacol Exp Ther; 1996 Jun; 277(3):1237-46. PubMed ID: 8667184
[TBL] [Abstract][Full Text] [Related]
4. Tamsulosin: alpha1-adrenoceptor subtype-selectivity and comparison with terazosin.
Muramatsu I; Taniguchi T; Okada K
Jpn J Pharmacol; 1998 Nov; 78(3):331-5. PubMed ID: 9869267
[TBL] [Abstract][Full Text] [Related]
5. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
6. Alpha1L-adrenoceptors mediate contractions of the isolated mouse prostate.
Gray KT; Ventura S
Eur J Pharmacol; 2006 Jul; 540(1-3):155-61. PubMed ID: 16716294
[TBL] [Abstract][Full Text] [Related]
7. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
Lepor H; Gup DI; Baumann M; Shapiro E
Urology; 1988 Dec; 32(6 Suppl):21-6. PubMed ID: 2462301
[TBL] [Abstract][Full Text] [Related]
8. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Keledjian K; Kyprianou N
J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
[TBL] [Abstract][Full Text] [Related]
9. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
10. New alpha1-adrenoceptor antagonist, JTH-601, shows more than 10 times higher affinity for human prostates than arteries.
Takahashi M; Taniguchi T; Murata S; Okada K; Moriyama N; Yamazaki S; Muramatsu I
J Urol; 1999 Apr; 161(4):1350-4. PubMed ID: 10081906
[TBL] [Abstract][Full Text] [Related]
11. An investigation of the uroselective properties of four novel alpha(1a)-adrenergic receptor subtype-selective antagonists.
Pulito VL; Li X; Varga SS; Mulcahy LS; Clark KS; Halbert SA; Reitz AB; Murray WV; Jolliffe LK
J Pharmacol Exp Ther; 2000 Jul; 294(1):224-9. PubMed ID: 10871316
[TBL] [Abstract][Full Text] [Related]
12. In vivo measurement by [3H]Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics.
Yamada S; Ohkura T; Deguchi Y; Kimura R
J Pharmacol Exp Ther; 1999 Jun; 289(3):1575-83. PubMed ID: 10336555
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I.
Leonardi A; Hieble JP; Guarneri L; Naselsky DP; Poggesi E; Sironi G; Sulpizio AC; Testa R
J Pharmacol Exp Ther; 1997 Jun; 281(3):1272-83. PubMed ID: 9190863
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of isolated human prostate.
Kester RR; Mooppan UM; Gousse AE; Alver JE; Gintautas J; Gulmi FA; Abadir AR; Kim H
J Urol; 2003 Sep; 170(3):1032-8. PubMed ID: 12913765
[TBL] [Abstract][Full Text] [Related]
15. Human epididymal and prostatic tracts of vas deferens: different contraction response to noradrenaline stimulation in isolated organ bath assay.
Colabufo NA; Pagliarulo V; Berardi F; Contino M; Perrone R; Niso M; Albo G; de Rienzo G; Pagliarulo A
Eur J Pharmacol; 2007 Dec; 577(1-3):150-5. PubMed ID: 17900563
[TBL] [Abstract][Full Text] [Related]
16. Characterization of alpha 2-adrenoceptors mediating contraction of dog saphenous vein: identity with the human alpha 2A subtype.
MacLennan SJ; Luong LA; Jasper JR; To ZP; Eglen RM
Br J Pharmacol; 1997 Aug; 121(8):1721-9. PubMed ID: 9283709
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.
Nagarathnam D; Wetzel JM; Miao SW; Marzabadi MR; Chiu G; Wong WC; Hong X; Fang J; Forray C; Branchek TA; Heydorn WE; Chang RS; Broten T; Schorn TW; Gluchowski C
J Med Chem; 1998 Dec; 41(26):5320-33. PubMed ID: 9857099
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the alpha-adrenoceptor characteristics in human and canine prostate.
Hieble JP; Boyce AJ; Caine M
Fed Proc; 1986 Oct; 45(11):2609-14. PubMed ID: 2428671
[TBL] [Abstract][Full Text] [Related]
19. Quantitative imaging in live human cells reveals intracellular alpha(1)-adrenoceptor ligand-binding sites.
Mackenzie JF; Daly CJ; Pediani JD; McGrath JC
J Pharmacol Exp Ther; 2000 Aug; 294(2):434-43. PubMed ID: 10900216
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Benning CM; Kyprianou N
Cancer Res; 2002 Jan; 62(2):597-602. PubMed ID: 11809715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
